Seres Therapeutics Inc (MCRB.OQ)
MCRB.OQ on NASDAQ Stock Exchange Global Select Market
7.70USD
24 Apr 2018
7.70USD
24 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$7.70
$7.70
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
48,418
48,418
52-wk High
$17.33
$17.33
52-wk Low
$6.65
$6.65
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Roger Pomerantz |
60 | 2014 | Chairman of the Board, President, Chief Executive Officer |
Eric Shaff |
42 | 2018 | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer |
John Aunins |
56 | 2012 | Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing |
David Cook |
59 | 2012 | Chief Scientific Officer, Executive Vice President - Research & Development |
Thomas DesRosier |
62 | 2016 | Chief Legal Officer, Executive Vice President and Secretary |
- BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc
- BRIEF-Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln
- BRIEF-Seres Therapeutics Says Has Cash, Cash Equivalents And Investments Of $171.3 Mln
- BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
- Biotech firms race to recruit good bugs in war on cancer